Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.

Adult Busulfan / administration & dosage Disease-Free Survival Female Hematopoietic Stem Cell Transplantation Humans Male Middle Aged Myeloablative Agonists / administration & dosage Transplantation Conditioning
Busulfan Hematopoietic stem cell transplantation Pharmacokinetics

Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
02 2019
Historique:
received: 06 05 2018
accepted: 10 09 2018
pubmed: 24 9 2018
medline: 25 12 2019
entrez: 24 9 2018
Statut: ppublish

Résumé

Targeted busulfan dosing helps limit chemotherapy-related toxicity and optimize disease outcomes in hematopoietic stem cell transplantation (HCT). The objective of this study was to evaluate busulfan exposure from a pharmacokinetic (PK)-guided dosing strategy using a test dose. This retrospective evaluation included adult patients who underwent HCT at our institution with busulfan-based myeloablative (>9 mg/kg) conditioning between January 2014 and October 2015. A weight-based test dose of 0.8 mg/kg was used with PK assessments to predict area under the curve (AUC

Identifiants

DOI: 10.1016/j.bbmt.2018.09.017 PMID: 30244102
pubmed: 30244102
pii: S1083-8791(18)30574-3
doi: 10.1016/j.bbmt.2018.09.017
pii:
doi:

Substances chimiques

Myeloablative Agonists 0
Busulfan G1LN9045DK

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

391-397

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Jessica M Davis (JM)

Department of Pharmacy, Carolinas Healthcare System, Levine Cancer Institute, Charlotte, North Carolina.

Anastasia Ivanova (A)

Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Yunro Chung (Y)

Department of Biomedical Informatics, Arizona State University, Scottsdale, Arizona.

J Ryan Shaw (JR)

Department of Pharmacy, UNC Hospitals and Clinics, Chapel Hill, North Carolina.

Kamakshi V Rao (KV)

Department of Pharmacy, UNC Hospitals and Clinics, Chapel Hill, North Carolina.

Jonathan R Ptachcinski (JR)

Department of Pharmacy, UNC Hospitals and Clinics, Chapel Hill, North Carolina.

Andrew A Sharf (AA)

Bone Marrow Transplant and Cellular Therapy Program, UNC Hospitals and Clinics, Chapel Hill, North Carolina.

Jonathan S Serody (JS)

UNC Bone Marrow Transplant and Cellular Therapy Program and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Paul M Armistead (PM)

UNC Bone Marrow Transplant and Cellular Therapy Program and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

William A Wood (WA)

UNC Bone Marrow Transplant and Cellular Therapy Program and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

James M Coghill (JM)

UNC Bone Marrow Transplant and Cellular Therapy Program and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Katarzyna J Jamieson (KJ)

UNC Bone Marrow Transplant and Cellular Therapy Program and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Benjamin G Vincent (BG)

UNC Bone Marrow Transplant and Cellular Therapy Program and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Marcie L Riches (ML)

UNC Bone Marrow Transplant and Cellular Therapy Program and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Thomas C Shea (TC)

UNC Bone Marrow Transplant and Cellular Therapy Program and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Maurice D Alexander (MD)

Department of Pharmacy, UNC Hospitals and Clinics, Chapel Hill, North Carolina. Electronic address: Maurice.Alexander@unchealth.unc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Evaluation of a Test Dose Strategy for...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Acides du soufre › Acides sulfoniques › Acides alcanesulfoniques › Alcanesulfonates › Méthanesulfonates › Busulfan › Evaluation of a Test Dose Strategy for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Evaluation of a Test Dose Strategy for...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Evaluation of a Test Dose Strategy for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Evaluation of a Test Dose Strategy for...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Evaluation of a Test Dose Strategy for...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Agonistes myélo-ablatifs › Evaluation of a Test Dose Strategy for...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Conditionnement pour greffe › Evaluation of a Test Dose Strategy for...